FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037078831> ?p ?o ?g. }

• W3037078831 endingPage "e000958" @default.
• W3037078831 startingPage "e000958" @default.
• W3037078831 abstract "Background Rare cases of immune checkpoint inhibitor (ICI)-associated celiac disease (ICI-CeD) have been reported, suggesting that disruption of tolerance mechanisms by ICIs can unmask celiac disease (CeD). This study aims to characterize the clinicopathological and immunophenotypic features of ICI-CeD in comparison to ICI-associated duodenitis (ICI-Duo) and usual CeD. Methods A medical and pathological records search between 2015 and 2019 identified eight cases of ICI-CeD, confirmed by tTG-IgA. Nine cases of ICI-Duo, 28 cases of moderate CeD, as well as 5 normal controls were used as comparison groups. Clinical information was collected from the electronic medical records. Immunohistochemistry for CD3, CD8, T-cell receptor gamma/delta (γδ), programmed death ligand 1 (PD-L1), and programmed death 1 (PD-1) were performed, with quantification of intraepithelial lymphocyte (IEL) subsets in three well-oriented villi. CD68, PD-L1, and PD-1 were assessed as a percentage of lamina propria surface area infiltrated by positive cells. Statistical significance was calculated by the Student’s t-test and Fisher’s exact test. Results The eight patients with ICI-CeD (F:M=1:3) and nine patients with ICI-Duo (F:M=5:4) presented similarly with diarrhea (13/17) and abdominal pain (11/17) after a median of 1.6 months on ICI therapy. In patients with ICI-CeD, tTG-IgA ranged from 104 to >300 IU/mL. Histological findings in ICI-CeD and ICI-Duo were similar and included expansion of the lamina propria, active neutrophilic duodenitis, variably increased IELs, and villous blunting. Immunohistochemistry showed that the average number of IELs per 100 enterocytes is comparable between ICI-CeD and ICI-Duo, with increased CD3 + CD8 + T cells compared with normal duodenum but decreased γδ T cells compared with CeD. Average PD-L1 percentage was 9% in ICI-CeD and 18% in ICI-Duo, in comparison to <1% in CeD and normal duodenum; average PD-1 percentage was very low to absent in all cases (<3%). On follow-up, five patients with ICI-CeD improved on a gluten-free diet (GFD) as the sole therapeutic intervention (with down-trending tTG-IgA) while the other three required immunosuppression. All patients who developed ICI-Duo received immunosuppression with variable improvement in symptoms. Conclusions ICI-CeD resembles ICI-Duo clinically and histologically but shares the serological features and response to gluten withdrawal with classic CeD. Immunophenotyping of IELs in ICI-CeD and ICI-Duo also shows similar CD3, CD8, γδ T cell subsets, and PD-L1 populations, all of which differed quantitatively from usual CeD. We conclude that ICI-CeD is biologically similar to ICI-Duo and is likely a variant of ICI-Duo, but treatment strategies differ, with ICI-CeD often improving with GFD alone, whereas ICI-Duo requires systemic immunosuppression." @default.
• W3037078831 created "2020-07-02" @default.
• W3037078831 creator A5020748070 @default.
• W3037078831 creator A5027091100 @default.
• W3037078831 creator A5029362928 @default.
• W3037078831 creator A5036295356 @default.
• W3037078831 creator A5043698578 @default.
• W3037078831 creator A5046725885 @default.
• W3037078831 creator A5058321006 @default.
• W3037078831 creator A5067234837 @default.
• W3037078831 creator A5072389805 @default.
• W3037078831 creator A5079390751 @default.
• W3037078831 creator A5083431383 @default.
• W3037078831 creator A5087354897 @default.
• W3037078831 date "2020-06-01" @default.
• W3037078831 modified "2023-10-18" @default.
• W3037078831 title "Immune checkpoint inhibitor-associated celiac disease" @default.
• W3037078831 cites W1664299218 @default.
• W3037078831 cites W1966333023 @default.
• W3037078831 cites W1996049617 @default.
• W3037078831 cites W2028226617 @default.
• W3037078831 cites W2037280768 @default.
• W3037078831 cites W2045135131 @default.
• W3037078831 cites W2062716630 @default.
• W3037078831 cites W2099560139 @default.
• W3037078831 cites W2116287226 @default.
• W3037078831 cites W2119355233 @default.
• W3037078831 cites W2292645700 @default.
• W3037078831 cites W2747875205 @default.
• W3037078831 cites W2762379919 @default.
• W3037078831 cites W2782898385 @default.
• W3037078831 cites W2783137027 @default.
• W3037078831 cites W2789465165 @default.
• W3037078831 cites W2791483720 @default.
• W3037078831 cites W2804960176 @default.
• W3037078831 cites W2887577080 @default.
• W3037078831 cites W2888695906 @default.
• W3037078831 cites W2894177377 @default.
• W3037078831 cites W2900582712 @default.
• W3037078831 cites W2903072327 @default.
• W3037078831 cites W2943668434 @default.
• W3037078831 cites W2950627686 @default.
• W3037078831 cites W2962821767 @default.
• W3037078831 cites W2965174384 @default.
• W3037078831 cites W2967374075 @default.
• W3037078831 cites W2987833617 @default.
• W3037078831 cites W2988163635 @default.
• W3037078831 cites W2994201430 @default.
• W3037078831 cites W2998514790 @default.
• W3037078831 cites W81942398 @default.
• W3037078831 doi "https://doi.org/10.1136/jitc-2020-000958" @default.
• W3037078831 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7319774" @default.
• W3037078831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32581063" @default.
• W3037078831 hasPublicationYear "2020" @default.
• W3037078831 type Work @default.
• W3037078831 sameAs 3037078831 @default.
• W3037078831 citedByCount "33" @default.
• W3037078831 countsByYear W30370788312020 @default.
• W3037078831 countsByYear W30370788312021 @default.
• W3037078831 countsByYear W30370788312022 @default.
• W3037078831 countsByYear W30370788312023 @default.
• W3037078831 crossrefType "journal-article" @default.
• W3037078831 hasAuthorship W3037078831A5020748070 @default.
• W3037078831 hasAuthorship W3037078831A5027091100 @default.
• W3037078831 hasAuthorship W3037078831A5029362928 @default.
• W3037078831 hasAuthorship W3037078831A5036295356 @default.
• W3037078831 hasAuthorship W3037078831A5043698578 @default.
• W3037078831 hasAuthorship W3037078831A5046725885 @default.
• W3037078831 hasAuthorship W3037078831A5058321006 @default.
• W3037078831 hasAuthorship W3037078831A5067234837 @default.
• W3037078831 hasAuthorship W3037078831A5072389805 @default.
• W3037078831 hasAuthorship W3037078831A5079390751 @default.
• W3037078831 hasAuthorship W3037078831A5083431383 @default.
• W3037078831 hasAuthorship W3037078831A5087354897 @default.
• W3037078831 hasBestOaLocation W30370788311 @default.
• W3037078831 hasConcept C126322002 @default.
• W3037078831 hasConcept C142724271 @default.
• W3037078831 hasConcept C152605822 @default.
• W3037078831 hasConcept C167672396 @default.
• W3037078831 hasConcept C178498320 @default.
• W3037078831 hasConcept C181199279 @default.
• W3037078831 hasConcept C203014093 @default.
• W3037078831 hasConcept C204232928 @default.
• W3037078831 hasConcept C2777310793 @default.
• W3037078831 hasConcept C529295009 @default.
• W3037078831 hasConcept C55493867 @default.
• W3037078831 hasConcept C71924100 @default.
• W3037078831 hasConcept C86803240 @default.
• W3037078831 hasConcept C8891405 @default.
• W3037078831 hasConcept C90924648 @default.
• W3037078831 hasConceptScore W3037078831C126322002 @default.
• W3037078831 hasConceptScore W3037078831C142724271 @default.
• W3037078831 hasConceptScore W3037078831C152605822 @default.
• W3037078831 hasConceptScore W3037078831C167672396 @default.
• W3037078831 hasConceptScore W3037078831C178498320 @default.
• W3037078831 hasConceptScore W3037078831C181199279 @default.
• W3037078831 hasConceptScore W3037078831C203014093 @default.
• W3037078831 hasConceptScore W3037078831C204232928 @default.

• next